Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Experimental and Molecular Therapeutics

Abstract #3693: Sorafenib inhibits Stat3-regulated expression of prosurvival Mcl-1 and Bcl-xL proteins to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.

Shengbing Huang and Frank Sinicrope
Shengbing Huang
Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Sinicrope
Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

Background: Sorafenib, a multi-target kinase inhibitor, has been shown to downregulate the prosurvival Bcl-2 family protein, Mcl-1, by an as yet unclear mechanism. Signal transducer and activator of transcription 3 (Stat3) is constitutively active in human tumors and has been shown to regulate Mcl-1. Therefore, we determined if sorafenib can inhibit Stat3 signaling to downregulate Mcl-1. We also studied whether Mcl-1 suppression can potentiate apoptosis induction by TRAIL (TNF-related apoptosis-inducing ligand), a proapoptotic cytokine whose anti-tumor effects are negatively regulated by Mcl-1. Experimental Design: Human pancreatic cancer cell lines (PANC-1 and BxPC-3) were pre-incubated with sorafenib (Nexavar®) alone or followed by TRAIL and apoptosis was determined by annexin V labeling. Caspase-8,-9,-3 and poly (ADP-ribose) polymerase (PARP) cleavage, as well as Bax/Bak activation, were analyzed by immunoblotting. The effects of sorafenib on Stat3 phosphorylation (Tyr705) and downstream Mcl-1 and Bcl-xL protein expression were determined. Lentiviral shRNA was used to knockdown BRAF, Stat3, and Mcl-1 expression. Results: Sorafenib treatment inhibited Stat3 phosphorylation (Tyr705) and downregulated Mcl-1 and Bcl-xL proteins in a dose-dependent manner in both cell lines. Stat3 knockdown was shown to suppress Mcl-1 and Bcl-xL. Furthermore, knockdown of BRAF, a Raf kinase and target of sorafenib, inhibited Stat3 phosphorylation (Tyr705) and similarly inhibited Mcl-1 and Bcl-xL protein expression. Mcl-1 knockdown was shown to potentiate apoptosis induced by TRAIL, and pharmacologic suppression of Mcl-1 by sorafenib similarly enhanced TRAIL-mediated apoptosis that was associated with caspase-8,-9,-3 and PARP cleavage, as well as Bak activation. Conclusions: Sorafenib inhibits Stat3 phosphorylation to downregulate prosurvival Mcl-1 and Bcl-xL protein expression, resulting in augmentation of TRAIL-mediated apoptosis in human pancreatic cancer cells.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 3693.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #3693: Sorafenib inhibits Stat3-regulated expression of prosurvival Mcl-1 and Bcl-xL proteins to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract #3693: Sorafenib inhibits Stat3-regulated expression of prosurvival Mcl-1 and Bcl-xL proteins to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
Shengbing Huang and Frank Sinicrope
Cancer Res May 1 2009 (69) (9 Supplement) 3693;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #3693: Sorafenib inhibits Stat3-regulated expression of prosurvival Mcl-1 and Bcl-xL proteins to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
Shengbing Huang and Frank Sinicrope
Cancer Res May 1 2009 (69) (9 Supplement) 3693;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract 6237: Bone-targeted nanoparticle containing protein therapeutics as an effective delivery system for bone metastasis
  • Abstract 2932: CD59 facilitates tumor progression through activating TGF-β/Smad signaling pathway in hepatocellular carcinoma
  • Abstract 6381: NBS-1120: An e-NSAID with potent anti-cancer activity targets cell cycle proteins by generating polysulfides
Show more Experimental and Molecular Therapeutics

Kinase Inhibitors 2 -- Poster Presentations - Proffered Abstracts

  • Abstract #3700: The selective MEK inhibitor RDEA119: Synergy with multiple classes of anti-cancer agents
  • Abstract #3709: A novel inhibitor of AKT prevents UVB-induced signaling in human skin cancers
  • Abstract #3713: Preclinical pharmacology and antitumor activity of a new class of ATP-competitive and highly selective inhibitors of the mammalian target of rapamycin (mTOR)
Show more Kinase Inhibitors 2 -- Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement